By: ChinaBio® Today
February 11, 2013 at 09:58 AM EST
OxOnc to Partner with Pfizer on China Cancer Drug Trial
OxOnc Development LLP, an oncology company headquartered in Princeton, NJ, has signed a co-development agreement with Pfizer to conduct a Phase III clinical trial of a Pfizer cancer drug in China, Taiwan, Japan and South Korea. The drug, crizotinib (marketed as Xalkori®), will be tested in patients with advanced non-small cell lung cancer who have a ROS1 (c-ros) gene rearrangement (ROS1-positive). The drug is already approved in the US, Europe, China and Japan for NSCLC patients with the ALK genetic variation. More details.... Stock Symbol: (NYSE: PFE) Share this with colleagues: // //
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here